Compare XPER & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPER | LCTX |
|---|---|---|
| Founded | 1990 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.1M | 388.6M |
| IPO Year | 2021 | 1996 |
| Metric | XPER | LCTX |
|---|---|---|
| Price | $7.96 | $1.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $11.67 | $6.25 |
| AVG Volume (30 Days) | 500.6K | ★ 1.3M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $448,105,000.00 | $14,556,000.00 |
| Revenue This Year | $4.03 | $109.40 |
| Revenue Next Year | $8.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $5.07 | $0.65 |
| 52 Week High | $8.50 | $2.09 |
| Indicator | XPER | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 67.15 | 44.36 |
| Support Level | $6.31 | $1.14 |
| Resistance Level | $8.50 | $1.80 |
| Average True Range (ATR) | 0.27 | 0.08 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 57.71 | 55.56 |
Xperi Inc is a media and entertainment technology company. Its technologies are integrated into consumer devices, connected cars, and a variety of media platforms globally, enabling audiences to connect with entertainment content in a more intelligent, immersive, and personal way. As its audiences engage with content on the platform, the company operates a cross-screen advertising solution that enables brands to reach millions of engaged consumers across rapidly expanding digital entertainment ecosystem. It operates in one reportable business segment and group its revenue into four categories: Pay-TV, Consumer Electronics, Connected Car and Media Platform. Geographically it operates in U.S. and Canada, Asia Pacific, Europe, Middle East and Africa, and Other countries.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.